This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2022
ASCO GU 2022 Prostate Cancer
ASCO GU 2022
Prostate Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Press Releases
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Carcinoma
ASCO GU 2022 Prostate Cancer
Viewing 41-60 of 10957 articles
ASCO GU 2024: Phase 3 KEYNOTE-676 Cohort A: Bacillus Calmette-Guérin with or Without Pembrolizumab for High-Risk Non–muscle-Invasive Bladder Cancer That Persists/recurs After BCG Induction
ASCO GU 2024: Advanced Urothelial Carcinoma Discussant
ASCO GU 2024: Keynote Lecture - Charting New Paths: Increasing Patient Representation in Genitourinary Malignancy Trials
ASCO GU 2024: A New Era in the Perioperative Management of Muscle Invasive Bladder Cancer
ASCO GU 2024: Drug Sequencing, Pairing, Switching, and the Role of Checkpoint Re-Challenging
ASCO GU 2024: Drug Shortages: Why Are They a Recurrent Issue and What Can Regulatory Do to Prevent Them?
ASCO GU 2024: Lessons Learned: What Can Other Disease Sites Teach Us About Practical Implications of Checkpoint Therapy in Urothelial Carcinoma?
ASCO GU 2024: Surgical Therapeutic Role for Node-Positive Disease: Does It Make a Difference?
ASCO GU 2024: Genetic Testing in RCC: Who, When, and How?
ASCO GU 2024: Management of Non-Clear Cell Renal Cell Carcinoma
ASCO GU 2024: The Emergent Role of Theranostics in Renal Cell Carcinoma
ASCO GU 2024: Harnessing the Power: Biologic Basis of Pairing and Sequencing Checkpoints with Other Therapy
ASCO GU 2024: The NEPI Trial: A Randomized Phase I/II Study of Neoadjuvant Treatment with 177-Lutetium-PSMA-617 with or without Ipilimumab in Patients with Very High-Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy
ASCO GU 2024: A Randomized, Non-Comparative, Phase II Multicenter Trial of Short-Term Darolutamide Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-Risk Prostate Cancer: DARIUS (AFU-GETUG P15)
ASCO GU 2024: Assessing the Clinical Utility of Rapid Post-Therapy Whole-Body Digital SPECT/CT in Evaluating Early Treatment Response of 177Lu-PSMA-617 Treatment
ASCO GU 2024: Infigratinib vs Placebo in Patients with Resected Urothelial Cancer Bearing FGFR3 Mutation or Fusion: Primary DFS Analysis from the Phase 3, Randomized PROOF302 Study
ASCO GU 2024: Association Between SPECT/CT Total Tumor Volume and New Lesions in Early Cycles of 177Lu-PSMA-617 and PFS and OS in Men with mCRPC
ASCO GU 2024: Neoadjuvant Combined Chemotherapy and Immunotherapy for Upper Tract Urothelial Carcinoma: Preliminary Results From a Phase II Study
ASCO GU 2024: Association Between PET-Based TheraP Eligibility and 177Lu-PSMA-617 Outcomes in VISION-Eligible Patients with mCRPC
ASCO GU 2024: Application of Artificial Intelligence Features of Nuclear Morphology from BLASST-1 (Bladder Cancer Signal Seeking Trial) of Nivolumab, Gemcitabine, and Cisplatin in Patients with MIBC Undergoing Cystectomy
1
2
3
4
5
6
7
8
9
10
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free